Tumour necrosis factor to treat chronic hepatitis B virus infection

Nick Sheron; Johnson Y.N. Lau; Helena M. Daniels; Jeff Webster; Adrian L.W.F. Eddleston; Graeme J.M. Alexander; Roger Williams

doi:10.1016/0140-6736(90)91866-9

Tumour necrosis factor to treat chronic hepatitis B virus infection

Nick Sheron^*
, Johnson Y.N. Lau
, Helena M. Daniels
, Jeff Webster
, Adrian L.W.F. Eddleston
, Graeme J.M. Alexander
, Roger Williams

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

29 Citations (Scopus)

Original language	English
Pages (from-to)	321-322
Number of pages	2
Journal	The Lancet
Volume	336
Issue number	8710
DOIs	https://doi.org/10.1016/0140-6736(90)91866-9
Publication status	Published - 4 Aug 1990
Externally published	Yes

Bibliographical note

Funding Information:
and to inhibit the release of interferon beta from these cells/ The concomitant rise in HBV DNA and AST while on treatment suggests that the increase in viral replication may have been accompanied by increased lysis of hepatocytes. This study has shown that long-term outpatient treatment with rTNF is possible. There was little evidence of systemic toxicity despite the presence of very high peak plasma TNF. This finding is noteworthy in view of the postulated toxicity of TNF in septic shock, which is associated with much lower serum TNF.8 None of our patients seroconverted to HBeAb despite the initial reduction in HBV DNA. A synergistic antiviral effect has been shown between TNF and interferon alpha in vitro studies 9 The addition of IFN-fx as a more potent direct antiviral agent or a longer duration of therapy might result in complete viral clearance. By simulating natural patterns of cytokine production the effectiveness of therapy for chronic HBV infection might be enhanced. We thank Dr R. Bown, Dr B. McDougall, Dr A. Forbes, and Dr J. L. Thirkettle for their help. N.S. is supported by the Wellcome Trust and J.Y.N.L. by the Croucher Foundation.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/0140-6736(90)91866-9

Cite this

@article{c5942b4ff1084c2b96aa822e2605b030,

title = "Tumour necrosis factor to treat chronic hepatitis B virus infection",

author = "Nick Sheron and Lau, \{Johnson Y.N.\} and Daniels, \{Helena M.\} and Jeff Webster and Eddleston, \{Adrian L.W.F.\} and Alexander, \{Graeme J.M.\} and Roger Williams",

note = "Funding Information: and to inhibit the release of interferon beta from these cells/ The concomitant rise in HBV DNA and AST while on treatment suggests that the increase in viral replication may have been accompanied by increased lysis of hepatocytes. This study has shown that long-term outpatient treatment with rTNF is possible. There was little evidence of systemic toxicity despite the presence of very high peak plasma TNF. This finding is noteworthy in view of the postulated toxicity of TNF in septic shock, which is associated with much lower serum TNF.8 None of our patients seroconverted to HBeAb despite the initial reduction in HBV DNA. A synergistic antiviral effect has been shown between TNF and interferon alpha in vitro studies 9 The addition of IFN-fx as a more potent direct antiviral agent or a longer duration of therapy might result in complete viral clearance. By simulating natural patterns of cytokine production the effectiveness of therapy for chronic HBV infection might be enhanced. We thank Dr R. Bown, Dr B. McDougall, Dr A. Forbes, and Dr J. L. Thirkettle for their help. N.S. is supported by the Wellcome Trust and J.Y.N.L. by the Croucher Foundation.",

year = "1990",

month = aug,

day = "4",

doi = "10.1016/0140-6736(90)91866-9",

language = "English",

volume = "336",

pages = "321--322",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8710",

}

TY - JOUR

T1 - Tumour necrosis factor to treat chronic hepatitis B virus infection

AU - Sheron, Nick

AU - Lau, Johnson Y.N.

AU - Daniels, Helena M.

AU - Webster, Jeff

AU - Eddleston, Adrian L.W.F.

AU - Alexander, Graeme J.M.

AU - Williams, Roger

N1 - Funding Information: and to inhibit the release of interferon beta from these cells/ The concomitant rise in HBV DNA and AST while on treatment suggests that the increase in viral replication may have been accompanied by increased lysis of hepatocytes. This study has shown that long-term outpatient treatment with rTNF is possible. There was little evidence of systemic toxicity despite the presence of very high peak plasma TNF. This finding is noteworthy in view of the postulated toxicity of TNF in septic shock, which is associated with much lower serum TNF.8 None of our patients seroconverted to HBeAb despite the initial reduction in HBV DNA. A synergistic antiviral effect has been shown between TNF and interferon alpha in vitro studies 9 The addition of IFN-fx as a more potent direct antiviral agent or a longer duration of therapy might result in complete viral clearance. By simulating natural patterns of cytokine production the effectiveness of therapy for chronic HBV infection might be enhanced. We thank Dr R. Bown, Dr B. McDougall, Dr A. Forbes, and Dr J. L. Thirkettle for their help. N.S. is supported by the Wellcome Trust and J.Y.N.L. by the Croucher Foundation.

PY - 1990/8/4

Y1 - 1990/8/4

UR - https://www.scopus.com/pages/publications/0025328715

U2 - 10.1016/0140-6736(90)91866-9

DO - 10.1016/0140-6736(90)91866-9

M3 - Letter

C2 - 1974016

AN - SCOPUS:0025328715

SN - 0140-6736

VL - 336

SP - 321

EP - 322

JO - The Lancet

JF - The Lancet

IS - 8710

ER -

Tumour necrosis factor to treat chronic hepatitis B virus infection

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this